Quantum BioPharma Receives BUY Rating and $45 Price Target from Kingswood Capital Partners

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has received a significant endorsement from Kingswood Capital Partners, which initiated coverage with a BUY rating and a US$45 price target. The independent research report, led by Kingswood Senior Equity Analyst Karen Sterling, PhD, CFA, provides a positive outlook for the biopharmaceutical company developing treatments for neurodegenerative, metabolic and alcohol misuse disorders. The valuation methodology employed discounted cash flow analysis, which assumes successful Phase 2 and 3 trials of lead candidate Lucid-MS between 2026 and 2028, followed by commercial launch in 2029.

The analyst coverage represents an important milestone for Quantum BioPharma as it validates the company's research and development pipeline. The BUY rating suggests that Kingswood Capital Partners believes the company's stock is undervalued relative to its future prospects. The $45 price target provides investors with a clear benchmark against which to measure the company's performance and potential returns. The report's independence is noteworthy as it was prepared without consideration from Quantum BioPharma, lending additional credibility to the positive assessment.

Quantum BioPharma's lead compound, Lucid-MS, represents a patented new chemical entity that has demonstrated the ability to prevent and reverse myelin degradation in preclinical models. Myelin degradation is the underlying mechanism of multiple sclerosis, making this development particularly significant for patients suffering from this challenging neurodegenerative disorder. The company maintains additional revenue streams through its ownership stake in Unbuzzd Wellness Inc., where it retains 20.11% ownership as of March 31, 2025, and receives royalty payments of 7% of sales from the unbuzzd(TM) product until payments total $250 million, after which the royalty drops to 3% in perpetuity.

For investors seeking additional information, the latest news and updates relating to QNTM are available in the company's newsroom at https://ibn.fm/QNTM. The full press release containing details about the analyst coverage can be viewed at https://ibn.fm/S27oE. This analyst initiation provides market participants with professional research coverage that may influence investment decisions and bring increased visibility to Quantum BioPharma's development programs and business strategy.